OverviewSuggest Edit

Abeona Therapeutics is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

TypePublic
Founded2013
HQDallas, US
Websiteabeonatherapeutics.com

Latest Updates

Employees (est.) (Mar 2020)88(+7%)
Job Openings16
Revenue (FY, 2018)$3 M(+259%)
Share Price (Aug 2020)$2.9 (-3%)
Cybersecurity ratingAMore

Key People/Management at Abeona Therapeutics

João Siffert

João Siffert

Director, Chief Executive Officer, Head of Research & Development and Chief Medical Officer
Steven H. Rouhandeh

Steven H. Rouhandeh

Director
Brian J. G. Pereira

Brian J. G. Pereira

Executive Chairman
Jay Bircher

Jay Bircher

Chief Technical Officer
Todd Wider

Todd Wider

Director
Edward Carr

Edward Carr

Chief Accounting Officer, Principal Financial Officer
Show more

Abeona Therapeutics Office Locations

Abeona Therapeutics has offices in Dallas, Cleveland, New York and Madrid
Dallas, US (HQ)
3333 Lee Pkwy #600
Cleveland, US
6555 Carnegie Ave 4th floor
New York, US
1330 6th Ave 33rd Floor
Madrid, ES
Av. de Manoteras, 30a
Show all (4)

Abeona Therapeutics Financials and Metrics

Abeona Therapeutics Revenue

Abeona Therapeutics's revenue was reported to be $3 m in FY, 2018 which is a 258.2% increase from the previous period.
USD

Net income (Q1, 2020)

(48.2m)

EBIT (Q1, 2020)

(48.2m)

Market capitalization (6-Aug-2020)

239.4m

Closing stock price (6-Aug-2020)

2.9

Cash (31-Mar-2020)

40.2m

EV

206.9m
Abeona Therapeutics's current market capitalization is $239.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

837.0k3.0m

Revenue growth, %

258%

General and administrative expense

10.9m20.1m20.7m

R&D expense

17.0m38.7m48.6m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

186.0k217.0k219.0k2.6m819.0k1.7m

General and administrative expense

3.0m2.6m2.2m2.9m4.6m5.0m5.7m5.6m4.7m6.4m

R&D expense

2.2m5.8m3.3m8.2m7.9m13.2m11.7m16.3m10.9m6.8m

Operating expense total

5.5m8.7m5.6m11.2m12.8m18.6m19.1m24.0m17.6m46.1m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

137.8m18.8m129.3m

Accounts Receivable

107.0k81.0k

Prepaid Expenses

2.7m3.8m3.1m

Current Assets

140.6m88.9m132.4m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

63.2m58.3m56.5m132.0m50.0m33.6m25.9m42.6m47.9m40.2m

Accounts Receivable

148.0k97.0k111.0k64.0k47.0k352.0k38.0k40.0k15.0k

Prepaid Expenses

463.0k867.0k1.8m2.1m1.9m2.0m3.4m2.3m1.7m2.7m

Current Assets

63.8m59.3m58.4m134.2m121.8m114.6m71.7m64.9m49.6m118.8m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(27.3m)(56.7m)(76.3m)

Depreciation and Amortization

741.0k2.4m7.8m

Accounts Payable

(1.3m)7.7m(1.7m)

Cash From Operating Activities

(22.9m)(39.1m)(62.8m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(5.2m)(13.5m)(18.9m)(8.5m)(20.2m)(36.6m)(18.6m)(42.5m)(59.9m)(48.2m)

Depreciation and Amortization

250.0k457.0k595.0k174.0k464.0k969.0k1.7m3.7m5.7m2.1m

Accounts Payable

(2.2m)(77.0k)(1.7m)3.5m3.4m7.9m(910.0k)3.0m(2.5m)

Cash From Operating Activities

(5.9m)(10.8m)(17.6m)(4.1m)(13.1m)(22.1m)(15.1m)(30.3m)(48.6m)(13.2m)
USDQ1, 2017

Revenue/Employee

9.8k

Financial Leverage

1.1 x
Show all financial metrics

Abeona Therapeutics Operating Metrics

FY, 2018FY, 2019

Product Candidates

8 8

Facility Space, sq. ft.

55.80 k57.40 k

Manufacturing Space, sq. ft.

43.70 k45.30 k
Show all operating metrics

Abeona Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Abeona Therapeutics LLCMay 15, 2015
MacroChem CorporationFebruary 25, 2009
Somanta Pharmaceuticals, Inc.January 04, 2008
Abeona Therapeutics Europe, S.L.
Virium Pharmaceuticals, Inc.

Abeona Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Abeona Therapeutics Revenue Breakdown

Embed Graph

Abeona Therapeutics revenue breakdown by business segment: 6.7% from Royalties and 93.3% from Foundation Revenues

Abeona Therapeutics Online and Social Media Presence

Embed Graph

Abeona Therapeutics News and Updates

Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting

NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two poster presentations related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) were featured a…

Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies

NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the Company’s pivotal Phase 3 VIITAL™ …

Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting

NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the u…

Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors

NEW YORK and CLEVELAND, June 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appointments that strengthen and expand the Company’s leadership. George Migausky and Paul Mann were appointed as…

Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids

NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associated virus (AAV) ca…

FINAL DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Reminds Abeona Therapeutics Inc. Investors of Important January 2nd Deadline in Securities Class Action

NEW YORK, Dec. 28, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abeona Therapeutics Inc. between May 31, 2018 and September 23, 2019, inclusive (the "Class Period") of the important January 2, 2020 lead plaintiff deadline...
Show more

Abeona Therapeutics Blogs

Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene…

Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New Yo…

Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™

Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment Dose-dependent and sustained reductions in disease-specific biomarkers denotes clear biologic effects of ABO-102 and ABO-101 First patient treated in cohort 3 of ABO-101 MPS IIIB trial; tot…

Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa

NEW YORK and CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the first World Congress on Epidermolysis Bullosa (EB2020), which is convening the world’s leading experts on …

Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Study open for enrollment and patient screening underway at Stanford University Company expects first patient to be treated in the first quarter of 2020 EB-101 manufactured at Abeona facility in Cleveland NEW YORK and CLEVELAND, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq…

Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten public offering, with a gross offering size of approximately $103.5 million, which includes the ful…
Show more

Abeona Therapeutics Frequently Asked Questions

  • When was Abeona Therapeutics founded?

    Abeona Therapeutics was founded in 2013.

  • Who are Abeona Therapeutics key executives?

    Abeona Therapeutics's key executives are João Siffert, Steven H. Rouhandeh and Brian J. G. Pereira.

  • How many employees does Abeona Therapeutics have?

    Abeona Therapeutics has 88 employees.

  • Who are Abeona Therapeutics competitors?

    Competitors of Abeona Therapeutics include Advance Medical, Ototech and Seven Springs Orthopaedics.

  • Where is Abeona Therapeutics headquarters?

    Abeona Therapeutics headquarters is located at 3333 Lee Pkwy #600, Dallas.

  • Where are Abeona Therapeutics offices?

    Abeona Therapeutics has offices in Dallas, Cleveland, New York and Madrid.

  • How many offices does Abeona Therapeutics have?

    Abeona Therapeutics has 4 offices.